Mizuho Reiterates Outperform on Corbus Pharmaceuticals, Maintains $74 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has reiterated an Outperform rating for Corbus Pharmaceuticals (NASDAQ:CRBP) and maintained a price target of $74.
September 20, 2024 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh has reiterated an Outperform rating for Corbus Pharmaceuticals and maintained a price target of $74, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100